Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract
Science Advances · 31.05.2024 · 10 (22)
DOI: 10.1126/sciadv.adn7786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 31.05.2024. Verfasst von Ozgun Kocabiyik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Immunity, Humoral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bill & Melinda Gates Foundation, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Here, we report a strategy to effectively concentrate immunogens and adjuvants in gut-draining lymph nodes (LNs) to induce gut-associated mucosal immunity. We prepared nanoemulsions (NEs) based on biodegradable oils commonly used as vaccine adjuvants, which encapsulated a potent Toll-like receptor agonist and displayed antigen conjugated to their surface. Following intraperitoneal administration, these NEs accumulated in gut-draining mesenteric LNs, priming strong germinal center responses and promoting B cell class switching to immunoglobulin A (IgA). Optimized NEs elicited 10- to 1000-fold higher antigen-specific IgG and IgA titers in the serum and feces, respectively, compared to free antigen mixed with NE, and strong neutralizing antibody titers against severe acute respiratory syndrome coronavirus 2. Thus, robust gut humoral immunity can be elicited by exploiting the unique lymphatic collection pathways of the gut with a lymph-targeting vaccine formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
ORCID-Profile: Ozgun Kocabiyik, Parastoo Amlashi, A Lina Vo, Sergio A Rodriguez-Aponte, Neil C Dalvie, J Christopher Love, Raiees Andrabi, Darrell J Irvine
Förderung
- Bill & Melinda Gates Foundation
- NCI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Kocabiyik, O., Amlashi, P., Vo, A. L., Suh, H., Rodriguez-Aponte, S. A., Dalvie, N. C., Love, J. C., Andrabi, R., & Irvine, D. J. (2024). Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract. Science Advances, 10(22). https://doi.org/10.1126/sciadv.adn7786
Vancouver
Kocabiyik O, Amlashi P, Vo AL, Suh H, Rodriguez-Aponte SA, Dalvie NC, et al. Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract. Science Advances. 2024;10(22). doi:10.1126/sciadv.adn7786
BibTeX
@article{Kocabiyik2024,
author = {Kocabiyik, Ozgun and Amlashi, Parastoo and Vo, A Lina and Suh, Heikyung and Rodriguez-Aponte, Sergio A and Dalvie, Neil C and Love, J Christopher and Andrabi, Raiees and Irvine, Darrell J},
title = {Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {22},
doi = {10.1126/sciadv.adn7786}
}
EUVIMED